US FDA GRANTS ORPHAN DRUG DESIGNATION TO PROMETIC’S PBI-4050 DRUG FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

February 17, 2015
Posted by: Prometic Prometic
Posted In: Press Releases 2015
X